Phase 3 development

Savara Raises $149.5M to Advance Rare Lung Therapeutic Program

LANGHORNE, Pa., November 2, 2025 — Savara Inc. (Nasdaq: SVRA), a clinical-stage biopharmaceutical company specializing in rare respiratory diseases,...

By cGxPwire Editor
November 2, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Phase 3 development

Savara Raises $149.5M to Advance Rare Lung Therapeutic Program